Advertisement
AKBA vs SCYX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Buy and SCYX is a StrongBuy.
AKBA's RSI Oscillator stoops into oversold zone
The RSI Oscillator for AKBA moved into overbought territory on November 05, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in 223 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AKBA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 47 cases where AKBA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In 64 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for AKBA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AKBA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.713) is normal, around the industry mean (7.445). P/E Ratio (-3.546) is within average values for comparable stocks, (0.293). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.115) is also within normal values, averaging (181.047).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. AKBA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
SCYX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
SCYX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where SCYX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for SCYX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 63 cases where SCYX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for SCYX just turned positive on October 28, 2026. Looking at past instances where SCYX's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCYX as a result. In 67 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
SCYX moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.491) is normal, around the industry mean (7.445). P/E Ratio (-3.626) is within average values for comparable stocks, (0.293). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.647) is also within normal values, averaging (181.047).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
AKBA | SCYX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 45 Fair valued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 95 | |
PRICE GROWTH RATING 1..100 | 84 | 81 | |
P/E GROWTH RATING 1..100 | 7 | 27 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SCYX's Valuation (21) in the Pharmaceuticals Other industry is in the same range as AKBA (45) in the Biotechnology industry. This means that SCYX’s stock grew similarly to AKBA’s over the last 12 months.
SCYX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as AKBA (100) in the Biotechnology industry. This means that SCYX’s stock grew similarly to AKBA’s over the last 12 months.
SCYX's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as AKBA (99) in the Biotechnology industry. This means that SCYX’s stock grew similarly to AKBA’s over the last 12 months.
SCYX's Price Growth Rating (81) in the Pharmaceuticals Other industry is in the same range as AKBA (84) in the Biotechnology industry. This means that SCYX’s stock grew similarly to AKBA’s over the last 12 months.
AKBA's P/E Growth Rating (7) in the Biotechnology industry is in the same range as SCYX (27) in the Pharmaceuticals Other industry. This means that AKBA’s stock grew similarly to SCYX’s over the last 12 months.
| AKBA | SCYX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 88% |
| Advances ODDS (%) | 4 days ago 84% | 4 days ago 83% |
| Declines ODDS (%) | 1 day ago 86% | 1 day ago 88% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Aroon ODDS (%) | 1 day ago 86% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKBA’s FA Score shows that 1 FA rating(s) are green while SCYX’s FA Score has 2 green FA rating(s).
- AKBA’s FA Score: 1 green, 4 red.
- SCYX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKBA’s TA Score shows that 3 TA indicator(s) are bullish while SCYX’s TA Score has 5 bullish TA indicator(s).
- AKBA’s TA Score: 3 bullish, 5 bearish.
- SCYX’s TA Score: 5 bullish, 3 bearish.
Price Growth
AKBA (@Pharmaceuticals: Generic) experienced а -42.67% price change this week, while SCYX (@Pharmaceuticals: Generic) price change was -14.51% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -5.51%. For the same industry, the average monthly price growth was -10.33%, and the average quarterly price growth was +1.98%.
Reported Earning Dates
AKBA is expected to report earnings on Mar 03, 2027.
SCYX is expected to report earnings on Mar 31, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-5.51% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
AKBA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with IPSC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then IPSC could also see price increases.
| Ticker / NAME | Correlation To AKBA | 1D Price Change % | ||
|---|---|---|---|---|
| AKBA | 100% | -38.75% | ||
| IPSC - AKBA | 38% Loosely correlated | -9.58% | ||
| SYRE - AKBA | 37% Loosely correlated | -2.47% | ||
| FENC - AKBA | 36% Loosely correlated | -9.28% | ||
| RXRX - AKBA | 36% Loosely correlated | -9.79% | ||
| KYMR - AKBA | 36% Loosely correlated | -5.97% | ||
More | ||||
SCYX and
Correlation & Price change
A.I.dvisor tells us that SCYX and ACET have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ACET's prices will move in lockstep.
| Ticker / NAME | Correlation To SCYX | 1D Price Change % | ||
|---|---|---|---|---|
| SCYX | 100% | -14.06% | ||
| ACET - SCYX | 27% Poorly correlated | -5.81% | ||
| ELAN - SCYX | 26% Poorly correlated | -6.44% | ||
| AKBA - SCYX | 25% Poorly correlated | -38.75% | ||
| CRDL - SCYX | 25% Poorly correlated | -8.27% | ||
| IMCC - SCYX | 24% Poorly correlated | -17.22% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CAAA | 20.02 | 0.09 | +0.43% |
| First Trust AAA CMBS ETF (CAAA) | |||
| PAI | 11.50 | -0.01 | -0.08% |
| Western Asset Investment Grade Income Fund | |||
| SOR | 46.53 | -0.30 | -0.65% |
| Source Capital | |||
| EPP | 55.63 | -0.88 | -1.56% |
| iShares MSCI Pacific ex-Japan ETF (EPP) | |||
| TXNU | 42.80 | -10.84 | -20.21% |
| Direxion Daily TXN Bull 2X ETF (TXNU) | |||